The observed safety findings and overall tolerability in patients with T2DM are consistent with those in previously reported studies in patients with cryopyrin-associated periodic syndrome, gouty arthritis and systemic juvenile idiopathic arthritis[21-23]. This evidence concerns the gene NLRP3 and gout.